QC Lab Extends Capabilities at Cambrex’s Milan Facility

Published on: 

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-05-01-2019, Volume 14, Issue 5

Cambrex’s expanded quality control laboratory supports generic API development.

Cambrex Corporation announced the opening of a 120-sq.-m quality control (QC) laboratory at its site in Paullo, Milan, Italy, expanding the existing QC facilities to analyze and test generic API products during development and manufacturing.

The additional laboratory space, which is operational following authorization by the Agenzia Italiana Del Farmaco, features a new polarimeter and infrared spectrometer, along with electronic data capturing software for traceability in line with regulatory requirements.

“Our facility in Milan is the center of the Cambrex’s generic API business, and this investment is the latest in a number of steps we have taken at the site to increase its efficiency and flexibility as we look to grow the portfolio of products that we offer,” commented Aldo Magnini, managing director, Cambrex Milan, in an April 23, 2019 press statement. “In the last year the company has made strategic investments to expand its capabilities in research and development, manufacturing, and now QC capabilities, as we look to take advantage of the opportunities that are arising in the generic market.”


Cambrex manufactures more than 70 generic APIs, which are produced to cGMP standards at the Milan site; seven production departments are supported by a pilot plant, kilo scale plant, and development and analytical laboratories.

Source: Cambrex Corporation